Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells

Acta Dermato-Venereologica

Volumn 86, Issue 1, 2006, Pages 13-16

  Inoue, Tomoko ^a   Katoh, Norito ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Betamethasone; IgE mediated; Mast cell number; Ovalbumin

Indexed keywords

BETAMETHASONE; BETAMETHASONE VALERATE; MARUISHI; OVALBUMIN; PETROLATUM; TACROLIMUS; UNCLASSIFIED DRUG; EMOLLIENT AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HYPERSENSITIVITY REACTION; MALE; MAST CELL DEGRANULATION; MOUSE; NICK END LABELING; NONHUMAN; OINTMENT; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; DEGRANULATION; DRUG EFFECT; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; MAST CELL; PHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BETAMETHASONE; CELL DEGRANULATION; EMOLLIENTS; GLUCOCORTICOIDS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOSUPPRESSIVE AGENTS; MALE; MAST CELLS; MICE; MICE, INBRED BALB C; OVALBUMIN; PETROLATUM; TACROLIMUS;

EID: 33744744995     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550510011501     Document Type: Article

References (22)

1. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 34: 883.
2. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1994; 133: 494-496.
3. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816-821.
4. Geba GP, Ptak W, Askenase PW. Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity. Immunology 2001; 104: 235-242.
5. Sawada K, Nagai H, Basaki Y, Yamaya H, Ikizawa K. Watanabe M, et al. The expression of cutaneous late phase reaction requires both IgE antibodies and CD4 T cells. Clin Exp Allergy 1996; 27: 225-231.
6. Schrans-Stassen BHGJ, Van de Kant HJG, De Rooij DG, Van Pelt AMM. Differential expression of c-kit in mouse undifferentiated and differentiating type A spermatogonia. Endocrinology 1999; 140: 5894-5900.
7. Ito F, Toyota N, Sakai H, Takahashi H, Iizuka H. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. Arch Dermatol Res 1999; 291: 275-283.
8. Pawankar R, Ra C. IgE-Fc epsilonRI-mast cell axis in the allergic cycle. Clin Exp Allergy 1998; 28 (Suppl 3): 6-14.
9. Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils andtenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 2004; 122: 1406-1412.
10. Kambe N, Irani AM, Schwarz LB. Mast cells and basophils. In: Leung DY, Bieber T, eds. Atopic dermatitis. New York: Marcel Decker, 2002: 285-326.
11. Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996; 97: 1064-1070.
12. Leung DYM, Diaz LA, DeLeo V, Soter NA. Allergic and immunologic skin disorders. JAMA 1997; 278: 1914-1923.
13. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 1992; 260: 680-688.
14. De Paulis A, Cirillo R, Ciccarelli A, De Crescenzo G, Oriente A, Marone G. Characterization of the anti-inflammatory effect of FK506 on human mast cells. J Immunol 1991; 147: 4278-4285.
15. Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson SD, et al. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokine. J Exp Med 1989; 70: 245-257.
16. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin biosynthesis. Nature 1979; 278: 269-274.
17. Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of cyclooxygenase/PGE isomerase. Br J Pharmacol 1989; 98: 1287-1295.
18. Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenan paw edemata - possible mechanism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical. Agents Actions 1984; 14: 228-237.
19. Inagaki N, Miura T, Nagai H, Ono Y, Koda A. Inhibition of vascular permeability increase in mice. Int Arch Allergy Appl Immunol 1988; 87: 254-259.
20. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997; 99: 1721-1728.
21. Lawlor F, Black AK, Murdoch RD, Greaves MW. Symptomatic dermographism: wealing, mast cells and histamine are decreased in the skin following long-term application ofa potent topical corticosteroid. Br J Dermatol 1989; 121: 629-634.
22. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.